Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 501–600 of 4,628
Homocysteine induces endothelial dysfunction via inhibition of arginine transport.
Jin, L., Caldwell, R. B., Li-Masters, T., & Caldwell, R. W. (2007) · PubMed · Cited by 95
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
Nishijima, N., Seike, M., Soeno, C., Chiba, M., Miyanaga, A., Noro, R., Sugano, T., Matsumoto, M., Kubota, K., & Gemma, A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3331 · Cited by 82
Schwarzkopf, L., Witt, S., Waelscher, J., Polke, M., & Kreuter, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0769-0 · Cited by 83
Nathan, S. D., Costabel, U., Albera, C., Behr, J., Wuyts, W. A., Kirchgaessler, K.-U., Stauffer, J. L., Morgenthien, E., Chou, W., Limb, S. L., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.04.016 · Cited by 79
Self-citationImaging research in fibrotic lung disease; applying deep learning to unsolved problems
Walsh, S. L. F., Humphries, S. M., Wells, A. U., & Brown, K. K. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30003-5 · Cited by 94
Self-citationPulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia
Omori, T., Tajiri, M., Baba, T., Ogura, T., Iwasawa, T., Okudela, K., Takemura, T., Oba, M. S., Maehara, T., Nakayama, H., et al. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.03.094 · Cited by 85
Enomoto, N., Mikamo, M., Oyama, Y., Kono, M., Hashimoto, D., Fujisawa, T., Inui, N., Nakamura, Y., Yasuda, H., Kato, A., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0004-4 · Cited by 82
The diagnosis and management of interstitial lung diseases
Wallis, A., & Spinks, K. (2015) · BMJ · doi:10.1136/bmj.h2072 · Cited by 90
Win, T., Screaton, N. J., Porter, J. C., Ganeshan, B., Maher, T. M., Fraioli, F., Endozo, R., Shortman, R. I., Hurrell, L., Holman, B. F., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3917-8 · Cited by 83
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 81
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
Harari, S., Caminati, A., Albera, C., Vancheri, C., Poletti, V., Pesci, A., Luppi, F., Saltini, C., Agostini, C., Bargagli, E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.010 · Cited by 78
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study
Cottin, V., Schmidt, A., Laura, C., Fanny, P., Céline, F.-M., Lay, K. L., & Bénard, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0166462 · Cited by 79
Self-citationYoon, J. H., Nouraie, M. S., Chen, X., Zou, R. H., Sellarés, J., Veraldi, K. L., Chiarchiaro, J., Lindell, K. O., Wilson, D. O., Kaminski, N., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0899-4 · Cited by 79
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Yoon, H.-Y., Park, S., Kim, D. S., & Song, J. W. (2018) · Respiratory Research · doi:10.1186/s12931-018-0907-8 · Cited by 78
Self-citationReichmann, W. M., Yu, Y., Macaulay, D. S., Wu, E. Q., & Nathan, S. D. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0161-5 · Cited by 85
Fujimoto, D., Kato, R., Morimoto, T., Shimizu, R., Sato, Y., Kogo, M., Ito, J., Teraoka, S., Nagata, K., Nakagawa, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168465 · Cited by 80
Faverio, P., Giacomi, F. D., Sardella, L., Fiorentino, G., Carone, M., Salerno, F. G., Ora, J., Rogliani, P., Pellegrino, G. M., Papa, G. F. S., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0643-3 · Cited by 90
Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0575-y · Cited by 77
Pulmonary fibrosis in the era of stratified medicine
Mathai, S. K., Newton, C. A., Schwartz, D. A., & Garcia, C. K. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-209172 · Cited by 77
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
Fujimoto, H., Kobayashi, T., & Azuma, A. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23321 · Cited by 89
Self-citationKotani, T., Masutani, R., Suzuka, T., Oda, K., Makino, S., & Ii, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15022-3 · Cited by 81
Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF
Farrand, E. D., Vittinghoff, E., Ley, B., Butte, A. J., & Collard, H. R. (2019) · Respirology · doi:10.1111/resp.13753 · Cited by 78
Self-citationGuillén‐Guío, B., Lorenzo-Salazar, J. M., Ma, S., Hou, P., Hernández-Beeftink, T., Corrales, A., García-Laorden, M. I., Jou, J., Espinosa, E., Muriel, A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30368-6 · Cited by 82
Justet, A., Klay, D., Porcher, R., Cottin, V., Ahmad, K., Molina‐Molina, M., Nunès, H., Reynaud‐Gaubert, M., Naccache, J. M., Manali, E. D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.03198-2020 · Cited by 87
Self-citationCombined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management
Hage, R., Gautschi, F., Steinack, C., & Schuurmans, M. M. (2021) · International Journal of COPD · doi:10.2147/copd.s286360 · Cited by 79
Bowman, W. S., Echt, G. A., & Oldham, J. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.680997 · Cited by 77
The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches
Wang, Y., Wei, J., Deng, H., Zheng, L., Yang, H. Y., & Lv, X. (2022) · Antioxidants · doi:10.3390/antiox11091685 · Cited by 95
Mechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 109
Li, M., Huang, H., Wei, X., Li, H., Li, J., Xie, B., Yang, Y., Fang, X., Wang, L., Zhang, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02262-3 · Cited by 110
Collum, S. D., Amione‐Guerra, J., Cruz-Solbes, A. S., DiFrancesco, A., Hernandez, A. M., Hanmandlu, A., Youker, K. A., Guha, A., & Karmouty‐Quintana, H. (2017) · Canadian Respiratory Journal · doi:10.1155/2017/1430350 · Cited by 88
“…mechanisms have not explicitly been identified in PH associated with IPF, it is conceivable that similar processes may be unique in patients in IPF and PH that can provide insight into the pathogenesis of PH in the setting of IPF in addition to providing unique therapeutic avenues for Group III PH.”
The Mighty Fibroblast and Its Utility in Scleroderma Research
Garrett, S. M., Frost, D. B., & Feghali‐Bostwick, C. A. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000240 · Cited by 95
Cerri, S., Monari, M., Guerrieri, A., Donatelli, P., Bassi, I., Garuti, M., Luppi, F., Betti, S., Bandelli, G., Carpano, M., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.105803 · Cited by 76
Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., & Voltolini, L. (2019) · Pulmonology · doi:10.1016/j.pulmoe.2018.06.003 · Cited by 81
“The INPULSIS I and II studies consistently demonstrated the efficacy of Nintedanib in reducing disease progression with a significant slowing down in the annual decline in FVC.(12,13) The Italian Medicines Agency AIFA approved Pirfenidone for use in Italy in June 2013, while Nintedanib was authorized in April 2016.”
ResultCellular Senescence in Lung Fibrosis
Hernandez-Gonzalez, F., Faner, R., Rojas, M., Agustí, A., Serrano, M., & Sellarés, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137012 · Cited by 76
Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine
Spagnolo, P., & Cottin, V. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103973 · Cited by 82
Self-citationIL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies
Passalacqua, G., Mincarini, M., Colombo, D., Troisi, G., Ferrari, M., Bagnasco, D., Balbi, F., Riccio, A., & Canonica, G. W. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.05.007 · Cited by 88
O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000108 · Cited by 75
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 80
Paulín, F., Doyle, T. J., Fletcher, E. A., Ascherman, D. P., & Rosas, I. O. (2015) · Revista de investigaci�n Cl�nica · doi:10.1016/s0034-8376(25)00249-9 · Cited by 94
Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD)
Sohal, S. S. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2016.11.006 · Cited by 75
Takezaki, A., Tsukumo, S., Setoguchi, Y., Ledford, J. G., Goto, H., Hosomichi, K., Uehara, H., Nishioka, Y., & Yasutomo, K. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182351 · Cited by 83
Kuse, N., Kamio, K., Azuma, A., Matsuda, K., Inomata, M., Usuki, J., Morinaga, A., Tanaka, T., Kashiwada, T., Atsumi, K., et al. (2019) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2020_87-302 · Cited by 78
Self-citationHetzel, J., Wells, A. U., Costabel, U., Colby, T. V., Walsh, S. L. F., Verschakelen, J., Cavazza, A., Tomassetti, S., Ravaglia, C., Böckeler, M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01520-2019 · Cited by 81
Self-citationHuang, S., Kronzer, V. L., Dellaripa, P. F., Deane, K. D., Bolster, M. B., Nagaraja, V., Khanna, D., Doyle, T. J., & Sparks, J. A. (2020) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-020-00160-z · Cited by 85
Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
Jouneau, S., Crestani, B., Thibault, R., Léderlin, M., Vernhet, L., Valenzuela, C., Wijsenbeek, M. S., Kreuter, M., Stansen, W., Quaresma, M., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01528-4 · Cited by 81
“In the two Phase III 52-week INPULSIS trials, nintedanib reduced the rate of decline in FVC in patients with mild or moderate impairment in lung function by approximately 50%, with an adverse event profile characterised mainly by gastrointestinal events [15].”
BackgroundMethodInfluentialSelf-citationGao, J., Kalafatis, D., Carlson, L., Pesonen, I., Li, C., Wheelock, Å. M., Magnusson, J. M., & Sköld, C. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01634-x · Cited by 79
Wang, Y., Liu, D., Zhang, T., & Xia, L. (2021) · Cancers · doi:10.3390/cancers13061360 · Cited by 80
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 124
Nintedanib in the treatment of idiopathic pulmonary fibrosis
Mazzei, M. E., Richeldi, L., & Collard, H. R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815579365 · Cited by 74
Self-citationRisk factors for an acute exacerbation of idiopathic pulmonary fibrosis
Kakugawa, T., Sakamoto, N., Sato, S., Yura, H., Harada, T., Nakashima, S., Hara, A., Oda, K., Ishimoto, H., Yatera, K., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0400-1 · Cited by 80
Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling
Guzy, R. D., Li, L., Smith, C., Dorry, S. J., Koo, H. Y., Chen, L., & Ornitz, D. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.791764 · Cited by 74
MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis
Mathai, S. K., Humphries, S. M., Kropski, J. A., Blackwell, T. S., Powers, J., Walts, A. D., Markin, C. R., Woodward, J., Chung, J. H., Brown, K. K., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212430 · Cited by 83
Self-citationSwigris, J. J., Brown, K. K., Abdulqawi, R., Buch, K. P., Dilling, D. F., Koschel, D., Thavarajah, K., Tomic, R., & Inoue, Y. (2018) · European Respiratory Review · doi:10.1183/16000617.0075-2018 · Cited by 74
Self-citationMa, X., Zhu, L., Kurche, J. S., Xiao, H., Dai, H., & Wang, C. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-216732 · Cited by 86
Giacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 84
“Both drugs have been demonstrated to slow down the decline in lung function and reduce the risk of acute respiratory exacerbations in patients with IPF [107,108].”
Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Kwon, B. S., Choe, J., Chae, E. J., Hwang, H. S., Kim, Y., & Song, J. W. (2021) · Respiratory Research · doi:10.1186/s12931-021-01879-6 · Cited by 79
HRCT of fibrosing lung disease
Jacob, J., & Hansell, D. M. (2015) · Respirology · doi:10.1111/resp.12531 · Cited by 79
Self-citationScreening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
Kreuter, M., Spagnolo, P., Wuyts, W. A., Renzoni, E. A., Koschel, D., Bonella, F., Maher, T. M., Kolb, M. R. J., Weycker, D. A., Kirchgässler, K.-U., et al. (2017) · Respiration · doi:10.1159/000468546 · Cited by 75
Self-citationInterstitial Pneumonia With Autoimmune Features (IPAF)
Fernandes, L., Nasser, M., Ahmad, K., & Cottin, V. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00209 · Cited by 72
“Nintedanib, a tyrosine kinase inhibitor with antifibrotic properties (34), has been approved in IPF, and was recently demonstrated to slow down disease progression in systemic sclerosis-associated ILD (35); approximately half the patients were also receiving mycophenolate in this study.”
BackgroundSelf-citationKenmotsu, H., Yoh, K., Mori, K., Ono, A., Baba, T., Fujiwara, Y., Yamaguchi, O., Ko, R., Okamoto, H., Yamamoto, N., et al. (2019) · Cancer Science · doi:10.1111/cas.14217 · Cited by 77
“Platelet count decreased 55 (60) 18 (20)”
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Huang, Y., Bose, S., Ma, S.-F., Kim, J. S., Schwab, A., Ting, C., Mou, K., Lee, C. T., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0117oc · Cited by 72
Self-citationStudying human respiratory disease in animals – role of induced and naturally occurring models
Williams, K. J., & Roman, J. (2015) · The Journal of Pathology · doi:10.1002/path.4658 · Cited by 85
Alveolar epithelial disintegrity in pulmonary fibrosis
Kulkarni, T., de Andrade, J. A., Zhou, Y., Luckhardt, T., & Thannickal, V. J. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00115.2016 · Cited by 83
The Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
“More recently, two compounds pleiotropic in their mechanisms of action—pirfenidone and nintedanib—have been approved for the treatment of IPF based on their ability to slow down the pace of functional decline and disease progression in phase 3 clinical trials (9, 10).”
BackgroundMethodQuercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling
Zhang, X., Cai, Y., Zhang, W., & Chen, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0302 · Cited by 80
Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities
Buendía-Roldán, I., Mejía, M. E., Navarro, C., & Selman, M. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.06.001 · Cited by 76
Self-citationNintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability
Vaidya, B., Shukla, S. K., Kolluru, S., et al. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.09.080 · Cited by 71
Bendstrup, E. M., Wuyts, W. A., Alfaro, T. M., Chaudhuri, N., Cornelissen, R., Kreuter, M., Nielsen, K. M., Münster, A. B., Myllärniemi, M., Ravaglia, C., et al. (2018) · Respiration · doi:10.1159/000495046 · Cited by 76
Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice
Sanders, Y. Y., Lyv, X., Zhou, Q. J., Xiang, Z., Stanford, D. D., Bodduluri, S., Rowe, S. M., & Thannickal, V. J. (2020) · JCI Insight · doi:10.1172/jci.insight.137127 · Cited by 75
Kang, J., Han, M., & Song, J. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-72607-1 · Cited by 84
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis
Adegunsoye, A., Morisset, J., Newton, C. A., Oldham, J. M., Vittinghoff, E., Linderholm, A., Strek, M. E., Noth, I., Garcia, C. K., Wolters, P. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02872-2020 · Cited by 75
Immunomodulatory treatment of interstitial lung disease
van den Bosch, L., Luppi, F., Ferrara, G., & Mura, M. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221117002 · Cited by 82
The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis
Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174547 · Cited by 74
Role of pirfenidone in the management of pulmonary fibrosis
Meyer, K. C., & Decker, C. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81141 · Cited by 79
The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis
Menou, A., Duitman, J., & Crestani, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.001 · Cited by 75
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0977oc · Cited by 70
Self-citationRecent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
Kondoh, Y., Cottin, V., & Brown, K. K. (2017) · European Respiratory Review · doi:10.1183/16000617.0050-2017 · Cited by 72
Self-citationIdiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs
Hadjicharalambous, M. R., & Lindsay, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020524 · Cited by 75
“In 2014, nintedanib was approved by the US Food and Drug Administration (FDA) for oral use in IPF patients after the completion of the INPULSIS-1 and IMPULSIS-2 trials [92].”
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Cottin, V., Richeldi, L., Rosas, I. O., Otaola, M., Song, J. W., Tomassetti, S., Wijsenbeek, M. S., Schmitz, M., Coeck, C., Stowasser, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01668-1 · Cited by 79
Self-citationMedical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Self-citationEGFR Signaling in Lung Fibrosis
Schramm, F., Schaefer, L., & Wygrecka, M. (2022) · Cells · doi:10.3390/cells11060986 · Cited by 77
Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review
Alsomali, H., Palmer, E., Aujayeb, A., & Funston, W. (2023) · Pulmonary Therapy · doi:10.1007/s41030-023-00216-0 · Cited by 88
Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation
Wettlaufer, S. H., Scott, J. P., McEachin, R. C., Peters-Golden, M. L., & Huang, S. K. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0468oc · Cited by 76
Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night
Schiza, S. E., Mermigkis, C. M., Margaritopoulos, G. A., Daniil, Z. D., Harari, S. A., Poletti, V. E., Renzoni, E. A., Torre, O., Visca, D., Bouloukaki, I., et al. (2015) · European Respiratory Review · doi:10.1183/16000617.00009114 · Cited by 76
IPF clinical trial design and endpoints
Nathan, S. D., & Meyer, K. C. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000091 · Cited by 72
Understanding COPD-overlap syndromes
Poh, T. Y., Aogáin, M. M., Chan, A., Yii, A. C. A., Yong, V. F. L., Tiew, P. Y., Koh, M. S., & Chotirmall, S. H. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1305895 · Cited by 76
Bale, S., Pooladanda, V., Sunkoju, M., & Godugu, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00248 · Cited by 73
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis
Schuliga, M. J., Grainge, C., Westall, G. P., & Knight, D. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.02.016 · Cited by 73
The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers
Ash, S. Y., Harmouche, R., Ross, J. C., Díaz, A. A., Hunninghake, G. M., Putman, R. K., Onieva, J. O., Martínez, F. J., Choi, A. M. K., Lynch, D. A., et al. (2016) · Academic Radiology · doi:10.1016/j.acra.2016.08.023 · Cited by 70
Matson, S. M., Lee, J. S., & Eickelberg, O. (2020) · European Respiratory Journal · doi:10.1183/13993003.02533-2020 · Cited by 82
Kato, R., Haratani, K., Hayashi, H., Sakai, K., Sakai, H., Kawakami, H., Tanaka, K., Takeda, M., Yonesaka, K., Nishio, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01201-z · Cited by 75
Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
Du, Y., Ma, J., Fan, Y., Wang, X., Zheng, S., Feng, J., Li, J., Fan, Z., Li, G., & Ye, Q. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1210675 · Cited by 72
Purinergic signaling in scarring
Ferrari, D., Gambari, R., Idzko, M., Müller, T., Albanesi, C., Pastore, S., Manna, G. L., Robson, S. C., & Cronstein, B. N. (2015) · The FASEB Journal · doi:10.1096/fj.15-274563 · Cited by 78
Ryerson, C. J., Tan, B., Fell, C. D., Manganas, H., Shapera, S., Mittoo, S., Sadatsafavi, M., To, T. M., Gershon, A. S., Fisher, J. H., et al. (2016) · Canadian Respiratory Journal · doi:10.1155/2016/3562923 · Cited by 79
Self-citationProfile of nintedanib in the treatment of solid tumors: the evidence to date
Awasthi, N., & Schwarz, R. E. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s78805 · Cited by 71
WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts
Klee, S., Lehmann, M., Wagner, D. E., Baarsma, H. A., & Königshoff, M. (2016) · Scientific Reports · doi:10.1038/srep20547 · Cited by 69
Rowbottom, M. W., Bain, G., Calderon, I., Lasof, T., Lonergan, D. G., Lai, A. G., Huang, F., Darlington, J. V., Prodanovich, P., Santini, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00345 · Cited by 71
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martinez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 68
Self-citation
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.